Screener
Climb Bio, Inc. CLYM Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Climb Bio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Climb Bio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210357
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Proceeds from exercise of stock options | 5 | — |
| Net cash provided by financing activities | 5 | — |
| Effect of exchange rate changes on cash and cash equivalents | — | (24) |
| Net change in cash and cash equivalents | (27,329) | (58,209) |
| Cash and cash equivalents at beginning of period | 35,685 | 87,229 |
| Cash and cash equivalents at end of period | $8,356 | $29,020 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for leases included in operating cash outflows | $73 | $69 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Climb Bio, Inc.'s net change in cash?
- Climb Bio, Inc. (CLYM) reported net change in cash of -$27.33M in Q1 2026.
- How has Climb Bio, Inc.'s net change in cash changed year-over-year?
- Climb Bio, Inc.'s net change in cash increased by 53.1% year-over-year, from -$58.21M to -$27.33M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Climb Bio, Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude